| Q45740493 | 48-mer synthetic peptide analogue of the hepatitis B virus "a" determinant induces an anti-HBs antibody response after a single injection |
| Q37333982 | A function essential to viral entry underlies the hepatitis B virus "a" determinant |
| Q33688319 | A peptide mimotope of hepatitis C virus E2 protein is immunogenic in mice and block human anti‐HCV sera |
| Q33348606 | A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients |
| Q41350716 | A surrogate hepatitis B virus antigenic epitope represented by a synthetic peptide and an internal image antiidiotype antibody |
| Q38971424 | Antibody affinity and IgG subclass of responses to tetanus toxoid in patients with rheumatoid arthritis and systemic lupus erythematosus. |
| Q37252387 | Antibody avidity in humoral immune responses in Bangladeshi children and adults following administration of an oral killed cholera vaccine |
| Q42088091 | Antibody responses to recombinant and plasma derived hepatitis B vaccines. |
| Q93647942 | Controversies in immunization against hepatitis B |
| Q39416652 | Epitope mapping of HBsAg using a panel of human anti-HBs antibodies |
| Q34251847 | Epitope reactions can be gauged by relative antibody discriminating specificity (RADS) values supported by deletion, substitution and cysteine bridge formation analyses: potential uses in pathogenesis studies |
| Q34784288 | Hepatitis B surface antigen variant with multiple mutations in the a determinant in an agammaglobulinemic patient |
| Q34807240 | Hepatitis B treatment: rational combination chemotherapy based on viral kinetic and animal model studies. |
| Q47825298 | Human T-cell recognition of synthetic peptides representing conserved and variant sequences from the merozoite surface protein 2 of plasmodium falciparum |
| Q40045663 | Hybrid hepatitis B virus nucleocapsid bearing an immunodominant region from hepatitis B virus surface antigen |
| Q45834810 | Immune response to uncoupled peptides of foot-and-mouth disease virus |
| Q39490668 | Immunity to hepatitis B: analysis of antibody and cellular responses in recipients of a plasma-derived vaccine using synthetic peptides mimicking S and pre-S regions |
| Q69857561 | Immunogenicity of recombinant hepatitis B vaccine |
| Q43768295 | Immunoselected hepatitis B virus mutant |
| Q45859875 | Kinetics of antibody response to hepatitis B virus determinants and to recombinant vaccines in Italy |
| Q44665833 | Mapping of linear B-cell epitopes of hepatitis B surface antigen |
| Q43988430 | Molecular, immunological and clinical properties of mutated hepatitis B viruses. |
| Q45556409 | Mutant hepatitis B virus surface antigens (HBsAg) are immunogenic but may have a changed specificity |
| Q45396854 | Mutations in the S gene region of hepatitis B virus genotype D in Turkish patients |
| Q36632713 | Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen |
| Q33671155 | Naturally occurring variants of hepatitis B virus |
| Q34490083 | New hepatitis B vaccines |
| Q68971495 | Novel hepatitis B vaccines |
| Q38014963 | Peptides: chemistry, biology, and pharmacology |
| Q37269641 | Potential role of IgG avidity for diagnosing toxoplasmosis |
| Q33867301 | Prevention of de novo HBV infection by the presence of anti-HBs in transplanted patients receiving core antibody-positive livers |
| Q43941277 | Production and immunological analysis of recombinant hepatitis B vaccine |
| Q39319841 | Production of anti-peptide specific antibody in mice following immunization with peptides conjugated to mannan |
| Q40064217 | Production of infectious hepatitis delta virus in vitro and neutralization with antibodies directed against hepatitis B virus pre-S antigens |
| Q43631632 | Prospects for second and third generation hepatitis B vaccines |
| Q72152756 | Protective efficacy of hepatitis B vaccination |
| Q45832685 | Recent rubella virus infection indicated by a low avidity of specific IgG. |
| Q92164835 | Roles of Hepatitis B Virus Mutations in the Viral Reactivation after Immunosuppression Therapies |
| Q45071887 | Rubella infection and reinfection distinguished by avidity of IgG. |
| Q54207383 | Sequential immunizations with a panel of HIV-1 Env virus-like particles coach immune system to make broadly neutralizing antibodies. |
| Q44093258 | Seroprotection associated with infant vitamin A supplementation given with vaccines is not related to antibody affinity to Hepatitis B and Haemophilus influenzae type b vaccines |
| Q34416294 | Structural and functional heterogeneity of naturally occurring hepatitis B virus variants. |
| Q36796177 | Structural factors modulate the activity of antigenic poliovirus sequences expressed on hybrid hepatitis B surface antigen particles |
| Q45415301 | Study on hepatitis B virus pre-S/S gene mutations of renal tissues in children with hepatitis B virus-associated membranous nephropathy |
| Q28542694 | Subgenotypes and mutations in the s and polymerase genes of hepatitis B virus carriers in the West Bank, palestine |
| Q41933761 | Surface protein mutations in chronic hepatitis B patients who received hepatitis B vaccine therapy |
| Q36799328 | The development of novel hepatitis B vaccines |
| Q36635593 | The hepatitis B virus and the host response |
| Q46422862 | The relative affinity of recombinant dihydrolipoamide transacetylase for autoantibodies in primary biliary cirrhosis |
| Q93535905 | Viral hepatitis |